Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | CAMKK2 | Q96RR4 | 3/20 | 0.35 |
| ▸ | FYN | P06241 | 2/20 | 0.34 |
| ▸ | BRD4 | O60885 | 8/20 | 0.33 |
| ▸ | BTK | Q06187 | 1/20 | 0.32 |
| ▸ | IGF1R | P08069 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13745576 | 0.81 | PTPN11 (0.35) | BRD4ALDH1A1 | |
| SCHEMBL13745693 | 0.78 | FYN (0.41) | PTGS2CAMKK2FYNBRD4MAOB | |
| SCHEMBL13746237 | 0.78 | CAMKK2 (0.36) | PTGS2CAMKK2FYNBRD4MAOB | |
| SCHEMBL8320586 | 0.77 | CAMKK2 (0.60) | CAMKK2IGF1R | |
| SCHEMBL13746227 | 0.77 | FYN (0.37) | CAMKK2FYNBRD4 | |
| SCHEMBL1487576 | 0.75 | HTR6 (0.45) | PTGS2CAMKK2FYNBRD4SCN9A | |
| SCHEMBL13745799 | 0.72 | BRD4 (0.41) | PTGS2CAMKK2FYNBRD4 | |
| SCHEMBL1487602 | 0.71 | BRD4 (0.56) | PTGS2CAMKK2FYNBRD4IGF1R | |
| SCHEMBL13746458 | 0.70 | BRD4 (0.41) | PTGS2CAMKK2FYNBRD4KMT2A | |
| SCHEMBL14031013 | 0.70 | BRD4 (0.41) | PTGS2CAMKK2FYNBRD4SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215771-A1 | JNK INHIBITORS | GRACZYK PIOTR | 2009-08-27 | — | — | US | disclosed |
| US-7432375-B2 | JNK inhibitors | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2008-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215771-A1 | JNK INHIBITORS | MAPKAPK2, MAPK1, MAPKAPK3 | PTGS2 712/4885CAMKK2 94/4885FYN 259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.